Pharma News, 2022

On Monday, Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. 

The public image of drugmakers has improved significantly during the pandemic, according to the latest annual survey by PatientView, a UK-based research and consulting firm. ...

Pfizer has recalled five lots of Accupril (Quinapril HCl), its blood pressure adjunctive therapy for heart failure, due to the presence of unacceptable levels of a nitrosamine. ...

Valneva said the European Medicines Agency (EMA) has asked for more data on the company’s COVID-19 vaccine candidate, VLA2001, which the agency is reviewing for a possible marketing authorization...

The FDA has granted a Priority Review designation to AstraZeneca’s Biologics License Application (BLA) for tremelimumab as adjunct therapy to the company’s blockbuster drug Imfinzi (durvalumab...

Seven companies have been named in advertisements for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. In addition, Janssen was publicly reprimanded.

Astellas Pharma said it will end three gene therapy programs for the treatment of patients with Duchenne muscular dystrophy (DMD) based on disappointing preclinical data, along with several other p...

A combination of high-dose Vitamin D, Omega-3s, and simple home strength exercises can help reduce cancer risk in healthy adults aged 70 or older by 61 per cent, claims a study. ...

Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East Coast. ...

The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.

A massive study has analyzed the genomes of cancer cells from more than 12,000 patients, identifying 58 new mutational signatures that offer clues to novel causes of cancer.  ...

Almost three-quarters of antibiotic prescriptions to patients aged 65 years or older and two-thirds to Black patients are inappropriate, according to a U.S. study of more than 7 billion visits to d...